NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

Edwards Lifesciences Corporation (NYSE:EW) Q3 2024 Earnings Conference Call October 24, 2024 5:30 PM ET Corporate Participants Mark Wilterding - Senior Vice President & Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Larry Wood - Corporate Vice President and Group President of TAVR and SSH Daveen Chopra - Corporate Vice President, TMTT Conference Call Participants Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Robbie ...

Edwards Lifesciences (EW) reported $1.35 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 8.5%. EPS of $0.67 for the same period compares to $0.59 a year ago. ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, CA, Oct. 24, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook • Q3 sales from continuing operations grew 9%; constant currency sales grew 10% 1 • ...

NEWTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences Corporation securities (NYSE: EW) between February 6, 2024, and July 24, 2024, inclusive (the “Class Period”). To join this case, go HERE. Investors who purchased Edwards stock during the Class Period may move the U.S. District Court for the Central District of California to appoint them as the lead ...

Core Viewpoint - A class action lawsuit has been filed against Edwards Life Sciences Corporation, alleging violations of federal securities laws related to misleading statements about its Transcatheter Aortic Valve Replacement (TAVR) platform and its financial performance during the class period from February 6, 2024, to July 24, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities that purchased Edwards securities during the specified class period and claims that the company and certain executives made materially false and misleading statements [1][3]. - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1]. Group 2: Company Background - Edwards Life Sciences is an international company focused on researching, developing, and providing products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions [3]. Group 3: Allegations and Financial Impact - The lawsuit alleges that the defendants concealed material adverse facts regarding the TAVR platform, emphasizing their commitment and confidence in its demand in lower-penetrated markets [3]. - On July 24, 2024, Edwards reported disappointing second-quarter financial results and reduced its revenue guidance for the TAVR platform, attributing the poor performance to increased pressure on hospital workflows from the growth of structural heart therapies [4]. - Following the announcement of these results, Edwards's stock price fell by $27.25 per share, representing a nearly 32% decline [4].

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Edward ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109173&from=3 CLASS PERIO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 23, 2024 (GLOBE ...